​​Boehringer Ingelheim Inks €410M Deal With Kyowa Kirin

By Yeji Jesse Lee · January 5, 2024, 8:58 PM EST

Pharmaceutical giant Boehringer Ingelheim announced Friday that it had entered into a €410 million ($449 million) licensing agreement with Japanese pharmaceutical company Kyowa Kirin to develop a new treatment for fibro-inflammatory...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login